To introduce human biomonitoring as a novel approach to study both exposure and as early indicators of effects related to the use of chemicals in hospital-based healthcare. This is expected to increase awareness and better understanding of how work…
ID
Source
Brief title
Condition
- Other condition
Synonym
Health condition
Risico op kanker en reproductietoxiciteit en aangeboren afwijkingen
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Cytotoxics (urinary metabolite)
* Cisplatrinum (urinary total platinum)
* Carboplatinum (urinary total platinum)
* Cyclophosphamide
* 5-Fluoruracel (urinary alpha-fluoro-beta-alanine, FBAL)
* Iphosphamide
* Methotrexate
* Doxorubicin
* Gemcitabine
* Docetaxel
* Etoposide
* Paclitaxel
* Cytarabine
Inhalation anaesthetics in end-exhaled air and urine (urinary metabolite)
* Desflurane
* Isofluorane
* Nitrous oxide
* Sevofluorane (trifluoroacetate, hexafluoro-isopropanol)
Disinfection in end-exhaled air (urinary metabolite)
* Ethanol
* Isopropyl alcohol (acetone)
Secondary outcome
In addition to aforementioned exposure biomarkers the following additional
parameters will be studied:
* Micronucleated peripheral blood lymphocyte (PBL-MN)
* Micronucleated reticulocyte (RET-MN)
* Micronucleated Buccal cells (B-MN)
* Comets
* Blood cell counts
* Interleukines, IFN-gamma and TNF-alpha
Background summary
Workers involved in hospital-based healthcare work with hazardous chemicals.
These exposures may result in uptake and potential health effects. Exposure
surveillance is required for health risk management and prevention of
occupational disease. Human biomonitoring by measurement of specific biomarkers
in body fluids is an effective method of exposure surveillance and prevention.
Study objective
To introduce human biomonitoring as a novel approach to study both exposure and
as early indicators of effects related to the use of chemicals in
hospital-based healthcare. This is expected to increase awareness and better
understanding of how work practices contribute to internal exposure to
chemicals and how these practices can be further improved to reduce the uptake
of these chemicals.
Study design
Cross sectional survey in nine countries
Study burden and risks
The burden for the participants consists of:
* collection of pre-shift and post shift urine samples;
* collection of blood by vena puncture;
* collection of hand wipes;
* carrying air sampling equipment during work hours;
* participating in an interview to collect contextual information (e.g. on
lifestyle and work-related factor);
* participating in a daily interview regarding the tasks performed during the
shift.
The risk of participation is considered negligible.
Heyendaalseweg 135
Nijmegen 6525 AJ
NL
Heyendaalseweg 135
Nijmegen 6525 AJ
NL
Listed location countries
Age
Inclusion criteria
- 18 y or higher age on the day of recruitment
- Employment in a healthcare or animal research facility
- Access to occupational healthcare provided by a certified service provider
- Exposure to one of the following substance groups during at least two shifts
per week: cytotoxics, inhalation anesthetics or hand disinfection products
Exclusion criteria
- Persons who (at the time of the study) have a household member or who care
for a patient receiving treatment with cytotoxics (at home or in hospital
outpatient clinic)
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL86107.091.24 |